CytRx Corporation (CYTR) had a rough trading day for Monday October 07 as shares tumbled 5.36%, or a loss of $-0.017 per share, to close at $0.30. After opening the day at $0.28, shares of CytRx Corporation traded as high as $0.32 and as low as $0.28. Volume was 81,480 shares over 33 trades, against an average daily volume of n/a shares and a total float of 33.64 million.
As a result of the decline, CytRx Corporation now has a market cap of $10.09 million. In the last year, shares of CytRx Corporation have traded between a range of $1.05 and $0.26, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
CytRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It is also engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release technology.
CytRx Corporation is based out of Los Angeles, CA and has some 6 employees. Its CEO is Steven A. Kriegsman.
CytRx Corporation is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.